I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The funders of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The South West Research Ethics committee approved the study (REC Reference: 12/SW/0323) in January 2013. The sponsor of the study was the Royal Devon and Exeter NHS Foundation Trust. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. None of the listed funders had a role in the design and conduct of the study collection, management, analysis, and interpretation of the data preparation, review, and decision to submit the manuscript for publication. The sponsor of the PANTS study is the Royal Devon and Exeter National Health Service Foundation Trust. Laboratory tests were undertaken by the Exeter Blood Sciences Laboratory at the Royal Devon & Exeter National Health Service Trust (). The drug and anti-drug antibody assays were provided at reduced cost by Immundiagnostik AG. DNA methylation processing was supported through a sponsored research agreement with AbbVie Inc. Healthcare, South Korea, and Cure Crohn's Colitis (Scottish IBD Charity). PANTS is an investigator-led study funded by CORE (renamed Guts UK in 2018), the research charity of the British Society of Gastroenterology, and by unrestricted educational grants from AbbVie Inc, USA, Merck Sharp & Dohme Ltd, UK, NAPP Pharmaceuticals Ltd, UK, Pfizer Ltd, USA, Celltrion Eilis Hannon, Claire Bewshea, Neil Chanchlani and Jonathan Mill declare no competing interests. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech and non-financial support from Tillotts, outside the submitted work. Tariq Ahmad reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik outside the conduct of the study. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, and personal fees and non-financial support from Dr Falk, outside the submitted work. Mark Reppell, Jeffrey F Waring, Valerie Pivorunas, Nizar Smaoui, Heath Guay are employees of AbbVie and may own stock/options. Simeng Lin reports non-financial support from Pfizer outside the submitted work. Conclusion Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy.
0 Comments
Leave a Reply. |